As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati (AMGN)
Mohammed Haneefa Nizamudeen As the FDA continues to mull the fate of Amgen's lung cancer drug Lumakras, Sanofi is reportedly moving in on Mirati (NASDAQ:MRTX), which has developed a rival product called Krazati. Analysts appear to be…
